EMA Authorised: Prometax (rivastigmine) — Almirall, S.A.

View source ↗

Summary

The EMA authorised Prometax (rivastigmine) for the treatment of Alzheimer's disease, Parkinson's disease, and dementia. The decision date is 14 April 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia
• Parkinson Disease

Drugs mentioned

• Prometax (rivastigmine)

Snippet

Status: Authorised. Therapeutic area: Alzheimer Disease;Parkinson Disease;Dementia. MAH: Almirall, S.A.. Decision date: 14/04/2025